New United States Pharmaceutical Tariffs Force Sourcing Realignment
New Section 232 tariffs on patented drugs and ingredients require immediate sourcing audits before the September deadline.
Patent Medicine Sourcing
Exclusive Acquisition
Procuring pharmaceutical products protected by intellectual property rights involves direct negotiation with the original manufacturer or authorized distributor. Organizations engaged in patent medicine sourcing must navigate the legal landscape of exclusivity periods and licensing agreements. These medications typically have no generic equivalents, making the primary developer the sole provider.
Buyers manage high costs by establishing long-term supply contracts or volume-based pricing.
Market Access
Securing the rights to distribute or use proprietary treatments requires a deep understanding of local regulatory approvals. For patent medicine sourcing, the availability of a drug depends on whether the manufacturer has registered the product in the specific jurisdiction. Procurement teams coordinate with medical boards to ensure that the chosen treatments align with clinical guidelines.
This coordination prevents the purchase of products that cannot be legally administered. Negotiators often discuss managed entry agreements to balance patient access with budget constraints. Reliable access to specialized therapies often depends on the strength of the relationship with the patent holder.
Supply Continuity
Maintaining a steady flow of proprietary drugs is necessary because alternative options are unavailable. Effective patent medicine sourcing includes contingency planning for manufacturing delays or logistical bottlenecks at the source. Clear communication regarding demand forecasts helps producers schedule their batches to avoid shortages.